Crinetics Pharmaceuticals Names Robert M. Cuddihy, M.D., Senior VP of Medical Affairs

Crinetics Pharmaceuticals, Inc. has announced the appointment of Dr. Robert M. Cuddihy as its new Senior Vice President of Medical Affairs. Dr. Cuddihy, a board-certified expert in endocrinology, diabetes, and metabolism, brings over 30 years of experience from both clinical practice and the pharmaceutical industry.

Scott Struthers, Ph.D., the founder and CEO of Crinetics, expressed enthusiasm about the new appointment, highlighting Dr. Cuddihy's extensive background and expertise. Struthers stated that Dr. Cuddihy’s experience will be invaluable as the company progresses with the development and potential commercialization of its investigational drugs, paltusotine and atumelnant, as well as its broader pipeline of discovery candidates. According to Struthers, Dr. Cuddihy's role will be critical in bolstering Crinetics' reputation within the medical community.

Dr. Cuddihy, in turn, expressed his eagerness to join Crinetics, emphasizing the severe impact of endocrine diseases on patients. He noted that the company’s innovative therapies have shown promising results in various endocrine diseases with significant unmet needs. Dr. Cuddihy is optimistic about the potential of these therapies to revolutionize treatment options.

Before joining Crinetics, Dr. Cuddihy held several prestigious roles. He was the section chief of endocrinology, diabetes, and metabolism at the Dartmouth Hitchcock Medical Center and Clinics, and an associate professor at the Geisel School of Medicine at Dartmouth. Dr. Cuddihy also served as the CEO of Capsida Biotherapeutics and held senior roles in medical affairs at Amgen, the Janssen Pharmaceutical Companies of Johnson & Johnson, and Sanofi. His areas of responsibility included oncology, immunology, cardiovascular and metabolism, nephrology, neuroscience, bone health, and biosimilars. Dr. Cuddihy began his career in academic medicine at institutions such as the Mayo Clinic, Massachusetts General Hospital, Harvard Medical School, the International Diabetes Center, and the University of Minnesota Medical School. He earned his Bachelor of Science with highest honors from the University of Massachusetts Amherst and his M.D. from the University of Massachusetts Medical School.

Crinetics Pharmaceuticals is a clinical-stage company focused on creating novel treatments for endocrine diseases and related tumors. One of their leading candidates, paltusotine, is an oral somatostatin receptor type 2 (SST2) agonist currently in Phase 3 trials for acromegaly and Phase 2 trials for carcinoid syndrome associated with neuroendocrine tumors. Another key candidate, atumelnant (CRN04894), is an oral ACTH antagonist in Phase 2 trials for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. All of Crinetics’ drug candidates are small molecule new chemical entities developed through in-house drug discovery, targeting a range of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes, and obesity.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!